Wells Fargo cuts Omnicell PT on lower 2025 revenue forecast

Omnicell

13/01/2025 12:42

** Brokerage Wells Fargo cuts PT of medical software company
Omnicell  OMCL.O  to $40 from $49; maintains "equal weight"
rating
    ** New PT is a 5.4% downside to the stock's last close
    ** Brokerage says OMCL is "poised to offer 2025 Product
revenue guidance below consensus when it reports its 4Q24
results"
    ** Brokerage lowers 2025 product revenue forecast to $596
mln from $643 mln
    ** Brokerage says XT Extend offsetting low backlog coverage
in 2025 "doesn't seem likely"
    ** OMCL's XT Extend is a healthcare tech upgrade for better
security and user experience
    ** Brokerage says OMCL's decision to exit its Medimat
Dispensing product line could drive "margin accretion" in 2025
    ** OMCL gained 19.2% in 2024

 (Reporting by Kamal Choudhury in Bengaluru)
 ((Kamal.Choudhury@thomsonreuters.com;))